Qlife Holding AB (publ) (QLIFE.ST)
SEK 2.1
(5.53%)
SEK 2.1
(5.53%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -50.75 Million SEK | -1357.27% |
| 2022 | -10.74 Million SEK | -124.13% |
| 2021 | 44.54 Million SEK | 24.82% |
| 2020 | 35.68 Million SEK | 266.19% |
| 2019 | 9.74 Million SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -92 Thousand SEK | 75.34% |
| 2024 Q1 | -373 Thousand SEK | 99.64% |
| 2023 FY | -156.64 Million SEK | -1357.27% |
| 2023 Q3 | 2.73 Million SEK | -35.66% |
| 2023 Q4 | -104.03 Million SEK | -3905.12% |
| 2023 Q1 | 6.24 Million SEK | 112.97% |
| 2023 Q2 | 4.24 Million SEK | -32.01% |
| 2022 Q3 | 13.12 Million SEK | 4.75% |
| 2022 Q2 | 12.52 Million SEK | 6.31% |
| 2022 Q1 | 11.78 Million SEK | -58.27% |
| 2022 FY | -10.74 Million SEK | -124.13% |
| 2022 Q4 | -48.17 Million SEK | -467.19% |
| 2021 Q1 | 13.01 Million SEK | -50.33% |
| 2021 FY | 44.54 Million SEK | 24.82% |
| 2021 Q4 | 28.23 Million SEK | 1047.34% |
| 2021 Q3 | 2.46 Million SEK | -79.45% |
| 2021 Q2 | 11.97 Million SEK | -8.02% |
| 2020 FY | 35.68 Million SEK | 266.19% |
| 2020 Q4 | 26.2 Million SEK | 466.68% |
| 2020 Q3 | 4.62 Million SEK | -52.17% |
| 2020 Q2 | 9.66 Million SEK | 542.46% |
| 2020 Q1 | 1.5 Million SEK | 306.16% |
| 2019 Q3 | 37 Thousand SEK | -99.09% |
| 2019 FY | 9.74 Million SEK | 0.0% |
| 2019 Q1 | 2.78 Million SEK | 0.0% |
| 2019 Q2 | 4.04 Million SEK | 45.42% |
| 2019 Q4 | -730 Thousand SEK | -2072.97% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Acarix AB (publ) | 5.29 Million SEK | 1058.146% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 116.884% |
| ADDvise Group AB (publ) | 300.6 Million SEK | 116.884% |
| Arcoma AB | 11.07 Million SEK | 558.432% |
| Bactiguard Holding AB (publ) | 139.98 Million SEK | 136.257% |
| BICO Group AB (publ) | 1.83 Billion SEK | 102.772% |
| Boule Diagnostics AB (publ) | 249.71 Million SEK | 120.324% |
| CellaVision AB (publ) | 463.04 Million SEK | 110.961% |
| Clinical Laserthermia Systems AB (publ) | 2.99 Million SEK | 1793.46% |
| Chordate Medical Holding AB (publ) | -28.41 Million SEK | -78.619% |
| C-Rad AB (publ) | 66.01 Million SEK | 176.881% |
| Duearity AB (publ) | -4.17 Million SEK | -1114.768% |
| Dignitana AB (publ) | 58.97 Million SEK | 186.064% |
| Episurf Medical AB (publ) | -41.8 Million SEK | -21.419% |
| Getinge AB (publ) | 13.43 Billion SEK | 100.378% |
| Scandinavian Real Heart AB (Publ) | -50.21 Million SEK | -1.067% |
| Iconovo AB (publ) | 17.57 Million SEK | 388.736% |
| Integrum AB (publ) | 690.56 Thousand SEK | 7449.521% |
| Luxbright AB (publ) | -2.79 Million SEK | -1714.632% |
| Mentice AB (publ) | 236.38 Million SEK | 121.471% |
| OssDsign AB (publ) | 83.64 Million SEK | 160.677% |
| Paxman AB (publ) | 12.61 Million SEK | 502.227% |
| Promimic AB (publ) | 38.51 Million SEK | 231.775% |
| SciBase Holding AB (publ) | 16.03 Million SEK | 416.474% |
| ScandiDos AB (publ) | 47.55 Million SEK | 206.725% |
| Sectra AB (publ) | 557.55 Million SEK | 109.103% |
| Sedana Medical AB (publ) | 108.98 Million SEK | 146.571% |
| Senzime AB (publ) | 8.33 Million SEK | 708.622% |
| SpectraCure AB (publ) | -9.22 Million SEK | -450.287% |
| Stille AB | 132.17 Million SEK | 138.399% |
| Vitrolife AB (publ) | 1.97 Billion SEK | 102.566% |
| Xvivo Perfusion AB (publ) | 416.91 Million SEK | 112.174% |